Entities

Develops diagnostic technology using nanotechnology to identify pathogens in patient samples.

Provides a digital platform for sharing and managing equity capital markets deal information between issuers, banks and investors.

Provides an AI-assisted talent-data and analytics platform for financial institutions and executive-search firms. It combines public information, machine-learning processing and human research to map talent markets, track career movements and compare teams. Users can search in natural language, analyze candidate markets and manage collaborative hiring research.

Provides resale services for apparel brands, handling collection, quality checks, pricing and logistics for secondhand products.

Provides digital freight forwarding and logistics services, with software for booking, tracking and managing shipments.

Provides an online library and streaming platform for academic conference presentations and scientific video content.

An early-stage venture firm founded by Sumeet Singh that invests in AI computing, developer infrastructure, energy, industrial technology and other companies built around technical breakthroughs.

Uses AI and automated laboratory experiments to discover proteins and enzymes for advanced materials, mineral processing and industrial manufacturing.

Develops a wearable headband that measures brain activity and delivers timed acoustic stimulation to help users fall asleep.

Builds a clinical intelligence platform that helps healthcare organizations assess health risks and support preventative care and healthy aging.

Develops genome engineering tools using integrases to support therapeutic development and manufacturing.

Develops CAR-T cell therapies for cancers with limited treatment options, including a CD5-targeted program for T-cell malignancies.

Provides diagnostic tests, laboratory services and digital care pathways for health systems, employers and other organizations.

Builds imaging hardware and software for digital diagnostic testing in animal health, human health and environmental monitoring.

Develops oral medicines for retinal vascular diseases to reduce vision loss and the need for repeated eye injections.

Develops AI models for cancer prognosis, treatment selection and drug development using cancer evolutionary biology.

Develops multispecific antibody treatments that recruit gamma delta T cells to attack cancer.

Develops home diagnostic devices designed to detect diseases earlier and guide patients toward medical care.

Exciva is a clinical-stage biotechnology company founded in 2016 in Heidelberg, Germany, developing therapies for neuropsychiatric symptoms of dementia and other brain disorders. Its investigational lead drug Deraphan combines dextromethorphan with deramciclane to address agitation in Alzheimer’s disease dementia. Following Phase1 development, it began the Phase2/3 SERENADA trial in April2026. The company was founded by Anton Bespalov, Hans Moebius and Sreenivasarao (Rao) Vepachedu; its current CEO is François Conquet. Its programs remain investigational, with efficacy being evaluated in clinical trials.

Uses AI to predict cancer mutations from routine pathology images, helping clinicians and researchers identify potential targeted treatments.

Develops gene-correction therapies using targeted DNA integration, including treatments for inherited blood disorders.

Discovers previously uncharacterized human proteins and develops medicines based on their biological functions.

New York-based AI-enabled biotechnology company, formerly VantAI, developing proximity-based medicines by making protein interactions programmable. Its integrated discovery platform combines generative AI, structural proteomics and experimental chemistry and biology to map protein interactions and design molecular glues, PROTACs and other proximity modulators. Co-founded by Zachary Carpenter and Luca Naef, the business spun out of Roivant in 2023 and rebranded as Proxima in January 2026. Its team spans machine learning, computational biology and chemistry, proteomics and drug discovery, with seven published scientific advisers. A January 2026 seed announcement disclosed $80 million led by DCVC; the June 2026 SEC amendment records $91,454,999 actually sold in the same offering. A separate July 2023 preferred-share financing raised $6 million from SK Inc. Commercial collaboration milestones and retained-investment fair values are not financing proceeds.

Develops genetic medicines using modified DNA to change how nucleic acids function in the body.

Operates veterinary clinics and virtual care services, combining preventative care, diagnostics and ongoing support for pet owners.

Develops antibodies and bispecific T-cell engagers that target solid tumors.

Andrew Beam is publicly identified by Lila as Chief Technology Officer. Works on machine learning, biological research and causal inference. Co-founded Generate and is a Harvard epidemiology associate professor; holds NC State computer-science degrees.

Life-sciences inventor and Flagship Pioneering partner who co-founded Sail Biomedicines and serves on its board.

Chris Fussell is publicly identified by Lila as President, Operations. Previously president of McChrystal Group following fifteen years as a US Navy SEAL. Holds University of Richmond and Naval Postgraduate School degrees.

Jawad Ahsan is publicly identified by Lila as COO & CFO. Previously CFO at Axon and Market Track after thirteen years at GE. Holds an MIT MBA and a Holy Cross economics degree.

John Gregoire is publicly identified by Lila as Chief Autonomous Science Officer. Previously a Caltech research professor leading high-throughput materials discovery. Works on autonomous experimentation and active learning; holds Cornell physics and Concordia degrees.

Julie Shah is publicly identified by Lila as Chief Robotics Officer. Heads MIT’s aeronautics and astronautics department and its Interactive Robotics Group. Previously worked at Boeing and holds MIT degrees; researches human-robot collaboration.

Luca Naef is CO-FOUNDER & CTO at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Matthew Porteus is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: Professor of Definitive and Curative Medicine, Stanford University School of Medicine.

Rafael Gómez-Bombarelli is publicly identified by Lila as CSO, Physical Sciences. Co-founded Lila and is an MIT materials-science professor researching machine learning, molecular modeling and materials discovery. Holds Salamanca chemistry degrees and co-founded Reverie Labs, acquired by Relay Therapeutics.

Zachary Carpenter is CO-FOUNDER & CEO at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Kiutra lists Ulrich Kruse in its Board and advisors directory as its TRUMPF Venture representative. The directory does not specify a separate director or adviser title.

Invests in private technology companies approaching an IPO or other liquidity event, using primary and secondary transactions. Its AI strategy backs computing infrastructure, semiconductors, robotics and enterprise software.

Berlin AI company developing production-planning software for manufacturers. Its platform organizes operational and machine data and combines mathematical optimization, machine-learning pipelines and agent-based automation to support scheduling, capacity planning and responses to production disruptions.

German AI company automating governance, risk and compliance controls. Its platform translates policies and control requirements into executable code for continuous testing and evidence generation, supported by a knowledge graph linking risks and controls. Distinct from Auxilius at auxilius.co.

University of Sheffield spinout developing fluidic self-assembly technology for MicroLED display manufacturing. Its Continuous-Flo process combines MicroLED ink with extensions to coating equipment, aiming to improve mass-transfer throughput and reduce display production costs.

Swiss industrial-AI company using computer vision and automation to monitor waste-to-energy, cement and biomass facilities. Its systems analyze waste streams and plant operations to improve safety, operational efficiency and automation.

AI-security company developing runtime controls for autonomous agents. Its platform evaluates actions against identity, task context and security policies, can block unauthorized actions before execution, and records auditable decisions. Distinct from the advertising-related Kontext business at kontext.so.

German digital-health company developing immersive virtual-reality applications to complement psychotherapy. It is advancing a VR-based digital therapeutic for children with ADHD, with clinical studies and regulatory approval still in progress. Its research also includes VR-based cognitive training and neurofeedback.

Swiss neurotechnology company developing Neuro Access, an intraoperative brain-imaging platform combining optical coherence tomography, navigation and AI-supported guidance. A minimally invasive probe aims to help surgeons visualize tissue and blood vessels during stereotactic procedures. The system is undergoing product development, clinical validation and regulatory preparation.

Munich medical-technology company developing a wearable muscle-computer interface that measures muscle signals and delivers neuromuscular electrical stimulation. Its non-invasive platform combines continuous diagnostics and personalized activation for rehabilitation and neurological applications, including research into Parkinson’s tremor and impaired motor control.

Develops medical imaging software that reconstructs arteries in 3D to help clinicians detect vascular disease and plan cardiovascular and neurovascular procedures.

Uses microfluidics to isolate viable organelles at industrial scale, enabling pharmaceutical researchers to screen drug candidates for brain diseases.

Develops prescription digital therapeutics that use immersive video games to treat depression.

Kiutra lists Christian Ziach in its Board and advisors directory as its High-Tech Gründerfonds representative. The directory does not specify a separate director or adviser title.